Table 2.
Pooled HRs/ORs for OS, DFS and pCR in subgroup analyses.
| Subgroup | OS | DFS | PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study group | HR [95%CI] | P value | I 2 | Study group | HR [95%CI] | P value | I 2 | Study group | OR [95%CI] | P value | I 2 | |
| Total | 8 | 1.64 [1.27, 2.11] | 0.0002 | 0% | 9 | 2.29 [1.54, 3.39] | <0.0001 | 44% | 13 | 1.51 [1.24, 1.84] | <0.0001 | 70% |
| Timing of detection | ||||||||||||
| Before neoadjuvant therapy | 6 | 1.70 [1.29, 2.25] | 0.0002 | 0% | 8 | 2.31 [1.49, 3.56] | 0.0002 | 51% | 11 | 1.41 [1.19, 1.67] | <0.0001 | 62% |
| After neoadjuvant therapy | 2 | 1.34 [0.71, 2.52] | 0.36 | 0% | 1 | 2.32 [0.75, 7.18] | 0.14 | NA | 2 | 4.38 [0.50, 38.75] | 0.18 | 89% |
| Mean/median age | ||||||||||||
| ≥50y | 4 | 1.65 [1.07, 2.55] | 0.02 | 0% | 7 | 2.58 [1.51, 4.41] | 0.0005 | 56% | 8 | 1.44 [1.18, 1.74] | 0.0002 | 69% |
| <50y | 4 | 1.63 [1.19, 2.23] | 0.002 | 0% | 2 | 1.84 [1.11, 3.04] | 0.02 | 0% | 5 | 2.14 [1.06, 4.32] | 0.03 | 77% |
| Region | ||||||||||||
| Asia | 5 | 1.68 [1.23, 2.30] | 0.001 | 0% | 5 | 3.45 [2.08, 5.73] | <0.00001 | 19% | 9 | 1.77 [1.23, 2.55] | 0.002 | 62% |
| Europe | 1 | 1.82 [1.06, 3.12] | 0.03 | NA | 2 | 1.49 [0.84, 2.63] | 0.17 | 42% | 3 | 1.49 [1.33, 1.66] | <0.00001 | 62% |
| multicenter | 2 | 1.14 [0.54, 2.43] | 0.73 | 0% | 2 | 1.72 [0.89, 3.33] | 0.11 | 0% | 1 | 1.08 [0.96, 1.22] | 0.2 | NA |
| PLR cut-off | ||||||||||||
| ≥150 | 5 | 1.67 [1.24, 2.24] | 0.0007 | 0% | 7 | 2.30 [1.49, 3.54] | 0.0002 | 51% | 4 | 3.78 [1.20, 11.87] | 0.02 | 64% |
| <150 | 3 | 1.56 [0.94, 2.57] | 0.08 | 0% | 2 | 2.72 [0.54, 13.67] | 0.22 | 49% | 6 | 1.50 [1.36, 1.66] | <0.00001 | 0% |
NA refers to no available data.